New weight-loss shot appears to outperform other obesity drugs on market
Summary
A new drug called retatrutide, developed by Eli Lilly, helped people lose up to 28% of their body weight in a clinical trial. The drug combines three hormones and is taken once a week by injection. It showed better results than other weight-loss drugs currently available.Key Facts
- Retatrutide led to an average weight loss of 70.3 pounds (28.3%) over 80 weeks in the highest dose group.
- The trial included 2,339 adults with obesity or overweight and at least one related health condition, but no diabetes.
- 45.3% of participants on the highest dose lost at least 30% of their body weight.
- Retatrutide combines GLP-1, GIP, and glucagon hormones to help metabolism, appetite control, and energy balance.
- Other drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy typically result in 14%-20% weight loss, less than retatrutide.
- Common side effects include nausea (up to 42%), diarrhea, constipation, and vomiting, with higher doses causing more side effects.
- About 65.3% of participants on the highest dose reduced their BMI below 30, which is the level used to define obesity.
- The drug is injected weekly, with the dose gradually increasing over time.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.